Last10K.com

Ascendis Pharma As (ASND) SEC Filing 20-F Annual report for the fiscal year ending Monday, December 31, 2018

Ascendis Pharma As

CIK: 1612042 Ticker: ASND

View differences made from one year to another to evaluate Ascendis Pharma As's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 20-F Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Ascendis Pharma As.

Continue

Assess how Ascendis Pharma As's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Ascendis Pharma As's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 20-F Annual Report

Document And Entity Information
Consolidated Cash Flow Statements
Consolidated Statements Of Changes In Equity
Consolidated Statements Of Financial Position
Consolidated Statements Of Profit Or Loss And Other Comprehensive Income
Consolidated Statements Of Profit Or Loss And Other Comprehensive Income (Parenthetical)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Additional Information (Detail)
Commitments And Contingencies - Summary Of Lease Commitment Under Operating Leases (Detail)
Contract Liabilities
Contract Liabilities - Additional Information (Detail)
Critical Accounting Judgments And Key Sources Of Estimation Uncertainty
Critical Accounting Judgments And Key Sources Of Estimation Uncertainty - Additional Information (Detail)
Distributable Equity
Finance Income And Finance Expenses
Finance Income And Finance Expenses (Tables)
Finance Income And Finance Expenses - Schedule Of Finance Income And Finance Expenses (Detail)
Financial Risk Management And Financial Instruments
Financial Risk Management And Financial Instruments (Tables)
Financial Risk Management And Financial Instruments - Additional Information (Detail)
Financial Risk Management And Financial Instruments - Schedule Of Financial Assets And Liabilities (Detail)
Financial Risk Management And Financial Instruments - Schedule Of Foreign Currency Sensitivity Analysis (Detail)
General Information
Intangible Assets
Intangible Assets (Tables)
Intangible Assets - Summary Of Goodwill (Detail)
Investment In Associate
Investment In Associate (Tables)
Investment In Associate - Additional Information (Detail)
Investment In Associate - Equity (Detail)
Investment In Associate - Schedule Of Financial Information Of Investment In Visen (Detail)
Investments In Group Enterprises
Investments In Group Enterprises (Tables)
Investments In Group Enterprises - Summary Of Investments In Group Enterprises (Detail)
Ownership
Ownership - Additional Information (Detail)
Property, Plant And Equipment
Property, Plant And Equipment (Tables)
Property, Plant And Equipment - Additional Information (Detail)
Property, Plant And Equipment - Summary Of Property, Plant And Equipment (Detail)
Related Party Transactions
Revenue
Revenue (Tables)
Revenue - Schedule Of Revenue Recognized In Consolidated Statements Of Profit Or Loss (Detail)
Segment Information
Segment Information - Additional Information (Detail)
Share Capital
Share Capital (Tables)
Share Capital - Additional Information (Detail)
Share Capital - Summary Of Number Of Shares (Detail)
Staff Cost
Staff Cost (Tables)
Staff Cost - Additional Information (Detail)
Staff Cost - Schedule Of Warrant Activity (Detail)
Staff Cost - Schedule Of Warrant Activity (Parenthetical) (Detail)
Staff Cost - Schedule Of Weighted Average Exercise Price And Weighted Remaining Contractual Life For Outstanding Warrants (Detail)
Staff Cost - Summary Of Fair Values For Warrant Grants (Detail)
Staff Cost - Summary Of Staff Costs Recognized In The Statement Of Profit And Loss (Detail)
Staff Cost - Summary Of Staffing Cost (Detail)
Staff Cost - Summary Of Warrant Compensation Cost (Detail)
Staff Cost - Warrant Activity - Additional Information (Detail)
Subsequent Events
Subsequent Events - Additional Information (Detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Additional Information (Detail)
Summary Of Significant Accounting Policies - Schedule Of Asset's Expected Useful Life (Detail)
Tax On Profit/(Loss) For The Year And Deferred Tax
Tax On Profit/(Loss) For The Year And Deferred Tax (Tables)
Tax On Profit/(Loss) For The Year And Deferred Tax - Additional Information (Detail)
Tax On Profit/(Loss) For The Year And Deferred Tax - Summary Of Tax On Profit/Loss And Deferred Tax (Detail)
Tax On Profit/(Loss) For The Year And Deferred Tax - Summary Of Tax On Profit/Loss And Deferred Tax (Parenthetical) (Detail)
Ticker: ASND
CIK: 1612042
Form Type: 20-F Annual Report
Accession Number: 0001193125-19-096759
Submitted to the SEC: Wed Apr 03 2019 5:22:00 PM EST
Accepted by the SEC: Wed Apr 03 2019
Period: Monday, December 31, 2018
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/asnd/0001193125-19-096759.htm